-transparent.png){kind=logo}
Based on results of simulation and empirical studies conducted within the Divisions of Biometrics, Center for Drug Evaluation and Research, Food and Drug Administration, and in collaboration with the National Toxicology Program, the Center has recently changed the significance levels for testing positive linear trend in incidence rate for common and rare tumors, respectively, from 0.01 and 0.05 to 0.005 and 0.025. The overall false positive rate resulting from the use of this new rule in the tests for linear trend in a two-species-two-sex study is about 10%, the rate that is judged as the most appropriate in a regulatory setting by the Center. This paper describes two of the studies.
K K Lin, and
M A Rahman
June 1988,
Biometrics,
K K Lin, and
M A Rahman
November 1986,
Fundamental and applied toxicology : official journal of the Society of Toxicology,
K K Lin, and
M A Rahman
July 1977,
Cancer research,
K K Lin, and
M A Rahman
April 2006,
Environmental health perspectives,
K K Lin, and
M A Rahman
November 1995,
Journal of biopharmaceutical statistics,
K K Lin, and
M A Rahman
February 1972,
British medical journal,
K K Lin, and
M A Rahman
June 2011,
NeuroImage,
K K Lin, and
M A Rahman
February 2015,
Attention, perception & psychophysics,
K K Lin, and
M A Rahman
June 1986,
Regulatory toxicology and pharmacology : RTP,
